**Technology Advisory Committee C Interests Register**

**Topic [ID6261]**

**Publication Date: 08/05/2024**

| Name | Role with NICE | Type of interest | Description of interest | Interestdeclared | Comments |
| --- | --- | --- | --- | --- | --- |
| Elizabeth Thurgar | TAC C Committee Member | Direct- financial | Elizabeth Thurgar has, in the last six months, provided consultancy advice for Kite in an unrelated indication, relapsed or refractory mantle cell lymphoma. | 19/02/2024 | It was agreed that Elizabeth Thurgar's declaration would not prevent her from participating in discussions on this appraisal |
| Satish Venkateshan | TAC C Committee Member | Direct- financial | Regeneron has been developing Covid-19 treatments like casirivimab and imdevimab monoclonal antibodies and next generation covid antibody in the pipeline. Satish Venkateshan works for Regeneron, pharmaceuticals/biotech company. Satish Venkateshan also owns shares in the company and has stock options. Satish Venkateshan was conflicted and did not attend this discussion. | 19/02/2024 | It was agreed that Satish Venkateshan's declaration would prevent him from participating in discussions on this appraisal |
| Dr Kate Ren | TAC C Committee Member | Non-financial professional interests | Dr Kate Ren is a co-author of the EAG report.Dr Kate Ren was conflicted and did not attend his discussion. | 19/02/2024 | It was agreed that Dr Kate Ren's declaration would prevent her from participating in discussions on this appraisal |